Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab and Roflumilast Added to R-CHOP for Treatment Naïve High-Risk DLBCL
NCT06977711Phase 1Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Jun 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of loncastuximab tesirine and roflumilast in diffuse large B-cell lymphoma (DLBCL), sponsored by UT Health San Antonio. Primary endpoint: Adverse Events up to 24 weeks. Started Jun 2025; status: recruiting.
02
Drugs
loncastuximab tesirineroflumilast
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06977711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06977711.